If the end of alcohol prohibition is any indication, the states that are first to legalize marijuana will have a long-term advantage over late adopters. That’s the key conclusion of a new study published this week.
A team of researchers wanted to know whether the quickness with which states took advantage of the opportunity to allow beer sales beginning in 1933 impacted the long-term health of the industry in each state.
Their study, published in the Journal of the Economic & Business History Society, showed that early adopters had significant short- and long-term advantages over states that ended up legalizing later. And that will likely prove to be the case with the marijuana legalization movement, too.
“In the long run, states that legalize in the earliest stages of this staggered removal of the drug’s prohibition may enjoy an early-adopter advantage with respect to the production and sale of marijuana as they gain a foothold in what may soon become a national (or international) market for the product,” the researchers wrote.
Twenty-one states legalized beer in April 1933, 22 states legalized throughout the rest of the year and the last five states legalized over the course of the following three and a half years. There was an industry-wide consolidation of breweries from 1934 to 1977, but data from the American Breweriana Association showed that breweries were more likely to survive the test of time and also expand in states that were quickest to legalize.
“The 722 breweries that were chartered in 1933 survived an average of 9.93 years, while the median brewery survived 4 years,” they wrote. “In 1950, when the number of breweries in the United States had fallen to around half of its 1935 number, 24.8 percent of the breweries chartered in 1933 were still in existence.”
Breweries in states that legalized just one year later weren’t so fortunate. Those 463 breweries survived an average of 4.9 years—and half had closed by the end of the year.
“Whether this can lend insight into the potential long- and short-term outcomes from the staggered state-level legalization of marijuana is worthy of discussion,” the researchers concluded.
Colorado Gov. Jared Polis (D) weighed in on that discussion recently. Recognizing the short-term economic benefits of the state’s legal marijuana system, which was one of the first to be implemented nationally, the governor joked that he’d “love other states to go slowly so that we can continue to see all these benefits for Colorado.”
Marijuana tourism has given the state “a lot of extra business,” he said. But as the study indicates, those short-term gains could be sustained for decades, giving Colorado a leg up as the legalization movement continues.
The rapid adoption of legal cannabis programs has also put pressure on states where legalization has yet to be realized. That’s especially true in the densely packed northeast, where governors of several states have cited reform efforts in neighboring states as a motivating factor to push forward with legalization legislation.
“Things have changed, mainly because all of our neighbors are moving forward,” Rhode Island Gov. Gina Raimondo (D) said earlier this month.” We’re not an island, in fact. Like it or not, we’re going to be incurring public safety and public health expenses because it’s legal in Massachusetts… And I think it is time for us to put together our own regulatory and taxing framework.”
Pennsylvania Gov. Tom Wolf (D), who previously said the timing wasn’t right to legalize in the state, said efforts to legalize in New York and New Jersey have changed his mind.
The decision to legalize in New York didn’t emerge in a vacuum, either. Gov. Andrew Cuomo (D) said the “facts have changed” when it comes to legalization because there are surrounding states where it’s “no longer a question of legal or illegal.”
“It’s legal in Massachusetts. It may be legal in New Jersey,” Cuomo said. “Which means for all intents and purposes it’s going to be here anyway.”
As the new study shows, those states that get ahead of their neighbors in legalizing cannabis first stand to potentially benefit over a long period of time.
Chocolate Complicates Marijuana Edibles Potency Testing, Scientists Find
Scientists recently discovered that there’s something about chocolate that can botch the potency testing of marijuana edibles.
In research presented at one of the world’s largest scientific conferences on Sunday, the study’s principle investigator David Dawson found that THC potency testing for cannabis edibles can be significantly impacted when the product contains chocolate. That finding has implications for regulators, manufacturers and consumers.
“My research focuses on cannabis potency testing because of the high stakes associated with it,” Dawson said in a press release ahead of the American Chemical Society conference.
He cited a California law stipulating that edible marijuana products that test 10 percent below what’s indicated on the label must be relabeled and said “it’s even worse if a product tests 10 percent or more above the labeled amount—then the entire batch must be destroyed.”
One of the most surprising findings from the experiment is that when it comes to chocolate marijuana edible potency testing, less appears to be more. That’s to say, when testing a vial of an edible that contains one gram of chocolate, the tests produced “more precise values than when we had two grams of the same infused chocolate in the vial.”
“This goes against what I would consider basic statistical representation of samples, where one would assume that the more sample you have, the more representative it is of the whole,” Dawson, of CW Analytical Laboratories, said.
“Simply changing how much sample is in the vial could determine whether a sample passes or fails, which could have a huge impact on the producer of the chocolate bars, as well as the customer who might be under- or overdosing because of this weird quirk of matrix effects.”
It’s not yet clear what about chocolate is complicating THC potency testing, but Dawson said that the fat content of the ingredient is likely a main factor, especially considering that THC is fat soluble. And because of that, the research will likely have implications for edibles that aren’t chocolate based, and possibly even products such as topical lotions.
Next steps for Dawson and other researchers include determining whether similar trends exist for other cannabinioids such as CBD. Given that the Food and Drug Administration is actively exploring regulations to allow hemp-derived CBD to the food supply and would be charged with ensuring quality control standards, the findings could prove relevant on the federal level, too.
Photo courtesy of Flickr/jeffreyw.
Federally Funded Journal Exposes How Marijuana Prohibition Puts Consumers At Risk
Federal dollars are supporting the publication of a recent report that highlights how marijuana prohibition puts cannabis consumers at risk due to the resulting lack of guidance on safety standards from regulators.
The article was published this week in Environmental Health Perspectives, an “an open-access journal published with support from” the National Institutes of Health (NIH). It looked at issues related to regulating cannabis quality, which includes ensuring that the products don’t contain dangerous contaminants such as metals, pesticides and microbes.
“At the federal level in the United States, cannabis is still considered an illegal drug,” the piece notes. “As a result, neither the Food and Drug Administration (FDA) nor the Environmental Protection Agency (EPA) has provided any guidance on how to regulate contaminants or on which cannabis-related exposures can be considered safe.”
“States have had to determine on their own how to protect millions of cannabis users, and they have come up with widely varying responses,” the report states. “The result is an uncertain and occasionally incoherent regulatory landscape.”
The use of butane to extract marijuana concentrates, the prevalence of microbial contamination and high concentrations of metals are all concerns that federal agencies like the FDA and EPA would presumably address—if cannabis wasn’t a federally banned substance.
There’s at least one recent, relevant example on the issue: EPA announced on Wednesday that it will be approving pesticide applications for hemp, which was federally legalized through the Farm Bill late last year, but such tools will not be approved for marijuana because of its status under federal law.
But as it stands, such regulations are made and enforced at the state-level, meaning there’s a lack of consistency across legal marijuana programs.
“States have become experts at taxing and controlling this industry, and public health and safety has generally been a secondary or even-later-down-the-line consideration,” Ben Gelt, board chair of the Cannabis Certification Council, was quoted as saying in the report. “I think that is shifting, to some degree. I think that these issues are going to inevitably bubble up.”
Considering that instances of contamination have been reported in legalized states, it’s within reason to assume that cannabis consumers in non-legal states face an even greater set of risks given the complete lack of quality control standards.
“No state has it right, and there’s still a long way to go, and there’s still a lot of research that needs to be done,” Gelt said. “All of the states have significant gaps in their policies when it comes to testing and ensuring product quality and quality assurance. It just depends on what state you’re in where the gap is.”
While Environmental Health Perspectives receives support from federal government sources, an article’s appearance in the publication “does not indicate that the National Institute of Environmental Health Sciences condones, endorses, approves, or recommends the use of any products, services, materials, methodology, or policies stated therein,” according to a disclaimer on the journal’s website.
“Conclusions and opinions are those of the individual authors and advertisers only and do not necessarily reflect the policies or views of Environmental Health Perspectives or the National Institute of Environmental Health Sciences,” the notice states.
Nonetheless, the irony of federal dollars being spent to circulate a report hosted on a dot gov website that highlights the public health harms of ongoing federal marijuana prohibition was not lost on NORML Political Director Justin Strekal.
“The flat Earth mentality of continuing to deny the fact that a sizable percentage of the public consumes cannabis is hurting our ability to derive evidence-based best practices that put people’s health first,” he said. “It is the height of absurdity that public resources were used to compile a report that essentially states that the government is helpless because they have chained their hands to their sides as a result of prohibition. We demand regulation, not incarceration.”
“When the Congress chooses to get serious about putting public safety ahead of political expediency, they will move one of the various proposals to remove marijuana from the Controlled Substances Act to a vote,” Strekal said.
Marijuana Flower Offers More Pain Relief Than Other Cannabis Products, Study Finds
Among the overwhelming variety of cannabis products available on the market today, the most effective for pain relief appears to be whole dried marijuana flower and products high in THC, a new study finds.
“Whole cannabis flower was associated with greater pain relief than were other types of products, and higher tetrahydrocannabinol (THC) levels were the strongest predictors of analgesia and side effects prevalence across the five pain categories,” researchers from the University of New Mexico wrote. “In contrast, cannabidiol (CBD) levels generally were not associated with pain relief except for a negative association between CBD and relief from gastrointestinal and non-specified pain.”
Using data from a mobile app that aims to educate users about cannabis products and help them track their experiences, the researchers found that most people who reported self-medicating with marijuana have short-term, yet significant, relief from pain. “In our sample,” they write, “we observed an average pain reduction of roughly 3 points on a standard 0 to 10 visual analogue pain scale, consistent with its application as a mid-level analgesic.”
The findings, published in Complementary Therapies in Medicine in late July, are the latest in a robust body of scientific literature that shows marijuana can help people with different kinds of pain.
The study’s goal was to gauge how the severity of pain changed and what side effects were experienced after cannabis consumption, and whether these effects differed by product. Researchers used information gleaned from Releaf App, a mobile software program developed by three of the study’s authors and released in 2016. The app allows users to monitor their symptoms before, during and after consuming cannabis, thus helping them to understand the differences between products and delivery methods.
The study—which calls the Releaf data set “the largest database of real-time cannabis administration sessions in the U.S”—analyzed 20,513 cannabis sessions recorded in the app by 2,987 people between June 6, 2016 and October 24, 2018.
“Perhaps the most surprising result,” lead author Xiaoxue Li said in a statement, “is just how widespread relief was with symptom relief reported in about 95 percent of cannabis administration sessions and across a wide variety of different types of pain.”
“The results suggest that cannabis flower with moderate to high levels of tetrahydrocannabinol is an effective mid-level analgesic.”
On average, users reported their starting pain to be 5.87 on a scale of 1 to 10. After consuming marijuana, that number fell to 2.77—a decrease of 3.1 points.
“Among the limited number of product characteristics that are typically made available to consumers, we found that consumption of whole, natural Cannabis flower was associated with greater anesthetic potential than were most other types of products,” the authors wrote.
The study also found:
- Patients whose cannabis sessions involved flower reported similar pain relief as those using concentrates and topicals. Edibles, pills and tinctures, however, offered less relief than flower.
- Concentrates were found to be associated with more negative side effects, which the researchers reasoned could be because of solvents and other additives, as well as the removal of most terpenoids, terpenes and flavonoids.
- Products labeled as hybrid strains were more effective at relieving pain than those labeled indica or sativa.
- Combustion method didn’t affect pain.
- Higher THC levels offered more pain relief, while higher CBD levels did not.
- Patients with back, joint or muscle pain, headache or migraine and non-specified pain saw more relief with high-THC products.
- Patients with gastrointestinal/abdominal-related pain found more relief with lower levels of THC.
As for other reactions, patients were more likely to report positive effects than negative effects: they cited dry mouth and feeling foggy as the most common negative ones, while feeling relaxed and peaceful were frequently reported as the most positive ones. Additionally, while CBD levels didn’t impact pain much, the cannabinoid did appear to decrease the likelihood of having negative side effects.
“The current findings,” the study concludes, “show that self-directed medical cannabis treatment, especially among users of higher THC products, is associated with significant improvements in at least short-term pain relief, perhaps a major reason why cannabis has become one of the most widely used medications in the United States.”
In a statement, Jacob Vigil, another study author and UNM associate professor of psychology, said the reason why dried cannabis flower may be more effective for pain is because of its “numerous constituents that possess analgesic properties beyond THC, including terpenes and flavonoids.” These compounds probably work together to increase cannabis’ therapeutic effects, he said.
“Our results confirm that cannabis use is a relatively safe and effective medication for alleviating pain, and that is the most important message to learn from our results,” Vigil continued. “It can only benefit the public for people to be able to responsibly weigh the true risks and benefits of their pain medication choices.”
Photo courtesy of WeedPornDaily.